UroGen Pharma (NASDAQ:URGN) Receives “Buy” Rating from D. Boral Capital

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $25.00 target price on the stock. D. Boral Capital’s price objective would suggest a potential upside of 137.19% from the stock’s current price.

A number of other research analysts have also commented on the stock. Oppenheimer reiterated an “outperform” rating and set a $40.00 price objective on shares of UroGen Pharma in a research note on Wednesday, October 16th. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a research note on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, UroGen Pharma presently has an average rating of “Buy” and an average target price of $43.70.

UroGen Pharma Price Performance

NASDAQ URGN opened at $10.54 on Wednesday. UroGen Pharma has a 12 month low of $9.78 and a 12 month high of $20.70. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm has a market capitalization of $247.16 million, a PE ratio of -3.35 and a beta of 1.08. The company’s 50 day simple moving average is $10.88 and its 200 day simple moving average is $12.39.

Insiders Place Their Bets

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares in the company, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On UroGen Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in URGN. KLP Kapitalforvaltning AS acquired a new position in UroGen Pharma in the 4th quarter worth approximately $59,000. China Universal Asset Management Co. Ltd. boosted its stake in UroGen Pharma by 90.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after purchasing an additional 3,856 shares during the period. BNP Paribas Financial Markets boosted its stake in UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after purchasing an additional 5,890 shares during the period. Oppenheimer & Co. Inc. acquired a new position in UroGen Pharma in the 4th quarter worth approximately $126,000. Finally, Intech Investment Management LLC acquired a new position in UroGen Pharma in the 3rd quarter worth approximately $155,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.